CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
AREN0321 COG Treatment of High Risk Renal Tumors: A Groupwide Phase II Study Pediatric CIRB
AREN03B2 COG Renal Tumors Classification; Biology; and Banking Study Pediatric CIRB
AREN0532 COG Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor: A Groupwide Phase III Study Pediatric CIRB
AREN0533 COG Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors: A Groupwide Phase III Study Pediatric CIRB
AREN0534 COG Treatment for Patients with Bilateral; Multicentric; or Bilaterally-Predisposed Unilateral Wilms Tumor: A Groupwide Phase III Study Pediatric CIRB
AREN1721 COG A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups Pediatric CIRB
AREN1921 COG Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT) Pediatric CIRB
AREN2231 COG Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT) Pediatric CIRB
ARET0231 COG A Single Arm Trial of Systemic and Subtenon Chemotherapy for Groups C and D Intraocular Retinoblastoma Pediatric CIRB
ARET0321 COG A Trial of Intensive Multi-Modality Therapy for Extra-Ocular Retinoblastoma: A Groupwide Phase III Study Pediatric CIRB